Colony-stimulating factors in the treatment of HIV-associated non-Hodgkin's lymphoma.
Treatment results using standard chemotherapeutic regimens for patients with intermediate and high-grade non-Hodgkin's lymphoma have been disappointing. For patients with HIV-associated lymphoma, whose bone marrow tolerance is so limited, conservative dose combination chemotherapy has been the only realistic option. Now, however, the availability of recombinant colony-stimulating factors allows more dose-intensive therapy to be used. Both recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor have undergone Phase I testing and have been shown to reduce bone marrow toxicity following combination chemotherapy in non-HIV-infected patients. While this may be a promising lead for the treatment of HIV-infected patients also, it must be noted that until randomized trials are performed, no clear effects on survival or response can be verified.